0001372514-26-000038.txt : 20260421 0001372514-26-000038.hdr.sgml : 20260421 20260421164643 ACCESSION NUMBER: 0001372514-26-000038 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260421 DATE AS OF CHANGE: 20260421 EFFECTIVENESS DATE: 20260421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980443284 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-581327 FILM NUMBER: 26880185 BUSINESS ADDRESS: STREET 1: 169 SAXONY RD. STREET 2: SUITE 212 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: 858-224-9600 MAIL ADDRESS: STREET 1: 169 SAXONY RD. STREET 2: SUITE 212 CITY: ENCINITAS STATE: CA ZIP: 92024 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 D 1 primary_doc.xml X0708 D LIVE 0001372514 KIORA PHARMACEUTICALS INC 169 SAXONY RD. SUITE 212 ENCINITAS CA CALIFORNIA 92024 858-224-9600 DELAWARE EYEGATE PHARMACEUTICALS INC Corporation true Brian Strem 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Executive Officer President and Chief Executive Officer Melissa Tosca 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Executive Officer Chief Financial Officer Carmine Stengone 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Director Aron Shapiro 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Director Lisa Walters-Hoffert 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Director Praveen Tyle 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Director David Hollander 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Director Erin Parsons 169 Saxony Rd. Suite 212 Encinitas CA CALIFORNIA 92024 Director Pharmaceuticals Decline to Disclose 06b false 2026-04-06 false true true true false 0 5000000 5000000 0 The common stock and warrants sold for a combined purchase price of $2.5429. Amount excludes any proceeds from a cash exercise of warrants. false 3 0 0 0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3. false KIORA PHARMACEUTICALS INC /s/ Melissa Tosca Melissa Tosca CFO 2026-04-21